|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
|
US4373071A
(en)
|
1981-04-30 |
1983-02-08 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
|
US4401796A
(en)
|
1981-04-30 |
1983-08-30 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US5153319A
(en)
|
1986-03-31 |
1992-10-06 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
|
FR2645866B1
(fr)
|
1989-04-17 |
1991-07-05 |
Centre Nat Rech Scient |
Nouvelles lipopolyamines, leur preparation et leur emploi
|
|
US5334761A
(en)
|
1992-08-28 |
1994-08-02 |
Life Technologies, Inc. |
Cationic lipids
|
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
EP0708178A1
(en)
*
|
1994-10-19 |
1996-04-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
|
|
US5965434A
(en)
|
1994-12-29 |
1999-10-12 |
Wolff; Jon A. |
Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
|
|
US5700642A
(en)
|
1995-05-22 |
1997-12-23 |
Sri International |
Oligonucleotide sizing using immobilized cleavable primers
|
|
ATE285477T1
(de)
|
1995-06-07 |
2005-01-15 |
Inex Pharmaceutical Corp |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US5705385A
(en)
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US5744335A
(en)
|
1995-09-19 |
1998-04-28 |
Mirus Corporation |
Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
WO2004011647A1
(en)
|
2002-07-26 |
2004-02-05 |
Chiron Corporation |
Modified small interfering rna molecules and methods of use
|
|
US7994149B2
(en)
|
2003-02-03 |
2011-08-09 |
Medtronic, Inc. |
Method for treatment of Huntington's disease through intracranial delivery of sirna
|
|
NZ592917A
(en)
|
2003-09-15 |
2012-12-21 |
Protiva Biotherapeutics Inc |
Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
|
|
EP2399924B1
(en)
|
2004-05-27 |
2015-01-28 |
Alnylam Pharmaceuticals, Inc. |
Nuclease resistant double-stranded ribonucleic acid
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
WO2007070705A2
(en)
*
|
2005-12-15 |
2007-06-21 |
The Trustees Of The University Of Pennsylvania |
Cationic lipid-mediated vectors
|
|
EP2049665A2
(en)
|
2006-07-28 |
2009-04-22 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
|
WO2009058911A2
(en)
|
2007-10-31 |
2009-05-07 |
Applied Biosystems Inc. |
Preparation and isolation of 5' capped mrna
|
|
WO2009082607A2
(en)
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
|
WO2009082817A1
(en)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
CA3252166A1
(en)
|
2008-01-02 |
2025-11-29 |
Arbutus Biopharma Corporation |
Screening method for selected amino lipid-containing compositions
|
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
US8389768B2
(en)
|
2008-05-19 |
2013-03-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions comprising novel cationic lipids
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
ES2646630T3
(es)
|
2008-11-07 |
2017-12-14 |
Massachusetts Institute Of Technology |
Lipidoides aminoalcohólicos y usos de los mismos
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
CA2750561C
(en)
|
2009-01-26 |
2017-10-10 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
|
MX342785B
(es)
|
2009-06-10 |
2016-10-12 |
Alnylam Pharmaceuticals Inc |
Formulacion mejorada de lipido.
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US8236943B2
(en)
|
2009-07-01 |
2012-08-07 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
HUE042177T2
(hu)
|
2009-12-01 |
2019-06-28 |
Translate Bio Inc |
Szteroidszármazék mRNS szállítására humán genetikai betegségekben
|
|
CA2784568A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Lipid particles for delivery of nucleic acids
|
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
US10849975B2
(en)
*
|
2011-02-03 |
2020-12-01 |
Thomas Jefferson University |
Multivalent vaccines for rabies virus and filoviruses
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012158736A1
(en)
|
2011-05-17 |
2012-11-22 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
PL3586861T3
(pl)
|
2011-06-08 |
2022-05-23 |
Translate Bio, Inc. |
Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
|
|
EP3354644A1
(en)
*
|
2011-06-08 |
2018-08-01 |
Translate Bio, Inc. |
Cleavable lipids
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2755986A4
(en)
|
2011-09-12 |
2015-05-20 |
Moderna Therapeutics Inc |
MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US8999950B2
(en)
|
2011-10-05 |
2015-04-07 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing aldehyde dehydrogenase
|
|
KR102451116B1
(ko)
*
|
2011-10-27 |
2022-10-06 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
|
|
US20140378538A1
(en)
|
2011-12-14 |
2014-12-25 |
Moderma Therapeutics, Inc. |
Methods of responding to a biothreat
|
|
WO2013090186A1
(en)
|
2011-12-14 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleic acids, and acute care uses thereof
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
JP2015510495A
(ja)
|
2011-12-21 |
2015-04-09 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
器官または器官移植片の生存可能性または寿命を延長する方法
|
|
EP2797634A4
(en)
|
2011-12-29 |
2015-08-05 |
Moderna Therapeutics Inc |
MODIFIED MRNAS FOR THE CODING OF CELL-PENETRATING POLYPEPTIDES
|
|
SG11201405157PA
(en)
|
2012-02-24 |
2014-10-30 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
HK1206644A1
(en)
*
|
2012-03-29 |
2016-01-15 |
Shire Human Genetic Therapies, Inc. |
Lipid-derived neutral nanoparticles
|
|
ES2762873T3
(es)
*
|
2012-03-29 |
2020-05-26 |
Translate Bio Inc |
Lípidos catiónicos ionizables
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US20140275229A1
(en)
|
2012-04-02 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
|
US20150050354A1
(en)
|
2012-04-02 |
2015-02-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the treatment of otic diseases and conditions
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
EP4331620A3
(en)
|
2012-12-07 |
2024-12-04 |
Translate Bio, Inc. |
Lipidic nanoparticles for mrna delivery
|
|
WO2014093574A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
US20140200261A1
(en)
|
2013-01-17 |
2014-07-17 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
US20160022774A1
(en)
|
2013-03-12 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Diagnosis and treatment of fibrosis
|
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
KR20210122917A
(ko)
*
|
2013-03-14 |
2021-10-12 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
US10130649B2
(en)
*
|
2013-03-15 |
2018-11-20 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
|
WO2014144711A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
SMT202100691T1
(it)
|
2013-07-11 |
2022-01-10 |
Modernatx Inc |
Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
EP3052479A4
(en)
|
2013-10-02 |
2017-10-25 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
US20170173128A1
(en)
|
2013-12-06 |
2017-06-22 |
Moderna TX, Inc. |
Targeted adaptive vaccines
|
|
US20150167017A1
(en)
|
2013-12-13 |
2015-06-18 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
BR112017006679A2
(pt)
|
2014-10-02 |
2017-12-26 |
Protiva Biotherapeutics Inc |
moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d
|
|
WO2016071857A1
(en)
|
2014-11-07 |
2016-05-12 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus expression
|
|
WO2016077123A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Multiparametric nucleic acid optimization
|
|
EP3461904A1
(en)
|
2014-11-10 |
2019-04-03 |
ModernaTX, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
|
EP3233132A4
(en)
|
2014-12-19 |
2018-06-27 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
US20180000953A1
(en)
|
2015-01-21 |
2018-01-04 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016118725A1
(en)
|
2015-01-23 |
2016-07-28 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
CA2979998A1
(en)
|
2015-03-20 |
2016-09-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for treating hypertriglyceridemia
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
MX2020011166A
(es)
|
2018-04-25 |
2022-10-19 |
Ethris Gmbh |
Agentes crioprotectores para formulaciones en forma de particulas.
|
